A 29-year-old man died after experiencing a fatal reaction linked to quitting smoking while taking anti-psychotic medication, an inquest has heard. Jack Burton, diagnosed with paranoid schizophrenia, was prescribed clozapine, an anti-psychotic drug known to require careful dosage adjustments in smokers.

Burton, who lived in Worcester, was prescribed a nightly dose of 525mg of clozapine. Due to his status as a heavy smoker, his medication dosage was higher than typical, as cigarette smoke accelerates the liver’s processing of certain drugs, including clozapine. However, after he stopped smoking while on holiday in North Yorkshire in October 2025, his usual medication dose became toxic because no reduction was made to account for the absence of cigarettes.

The coroner’s report indicated this led to a fatal increase in Burton’s clozapine blood levels. Evidence presented during the inquest suggested that if Burton had planned to quit smoking, he should have informed his psychiatrist so that his medication dose could have been appropriately lowered to prevent adverse effects such as seizures.

The assistant coroner for Worcestershire, Deborah Lakin, highlighted a significant lack of clinical guidance regarding the management of psychiatric medication for patients who stop smoking. During the inquest, conflicting testimony was given by two consultant psychiatrists on whether the focus should be on smoking reduction or cessation, underscoring the absence of standardized protocols.

Ms. Lakin noted, “There is no guidance on any standardized practice available to practitioners relating to asking questions and recording answers given when discussing possible symptoms of side effects of the medication.” She has since issued a prevention of future deaths report calling attention to the need for clearer clinical guidelines to avoid similar tragedies.

The inquest did not conclusively establish whether Burton had sought advice about potential medication adjustments upon quitting smoking or whether he received adequate information about the risks. The case raises concerns about the communication between mental health patients and their healthcare providers when lifestyle changes affect medication efficacy and safety.